Summary & Overview
HCPCS Q4280: Xcell Amnio Matrix, Per Square Centimeter
HCPCS Level II code Q4280 designates the Xcell amnio matrix billed per square centimeter as an add-on, list-separately item in addition to a primary procedure. This code identifies the use of a biologic amniotic membrane product applied to wounds or surgical sites to support tissue repair and healing. Nationally, add-on biologic product codes like Q4280 matter because they affect bundled procedure payments, utilization reporting, and clinical documentation for advanced wound care and surgical reconstruction.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and service setting, common modifiers associated with billing this add-on product (list provided separately), and what to expect when encountering Q4280 on a claim. The publication outlines reimbursement and billing considerations typical for add-on biologic matrices, clarifies sites of service where the product is commonly used, and highlights documentation elements that payers commonly require.
The piece presents national context rather than state-level policy, offering benchmarks and typical payer practices where available. Data not available in the input will be noted explicitly in relevant sections.
Billing Code Overview
HCPCS Level II code Q4280 describes Xcell amnio matrix, billed per square centimeter as an add-on product billed separately in addition to a primary procedure. The service represents the use of a processed amniotic membrane matrix product applied to a wound or surgical site to support tissue repair and regeneration.
Service Type: Advanced biologic/adjunct wound care product
Typical Site of Service: Outpatient surgical settings, hospital outpatient departments, wound care clinics, and ambulatory care centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric wound care patient with a chronic non-healing wound (for example, a diabetic foot ulcer, venous stasis ulcer, pressure ulcer, or complex surgical wound) that has failed conservative therapy and requires biologic amniotic membrane matrix placement to promote granulation and re-epithelialization. The patient is evaluated in an outpatient wound clinic or ambulatory surgical center by a wound care specialist (podiatrist, plastic surgeon, or general surgeon). Prior to the procedure, the wound is assessed, debrided as needed, and infection is controlled. The provider measures the wound surface area in square centimeters to determine the quantity of Q4280 units required. The amniotic matrix product is prepared and applied directly to the wound bed as an adjunct to the primary procedure (for example, wound debridement, excisional procedure, or skin grafting). The product is billed as an add-on item in addition to the primary procedure code that describes the debridement or grafting. Typical site of service is an outpatient wound care clinic, physician office, or ambulatory surgery center. Post-application care includes dressing changes, offloading if indicated, and routine wound follow-up visits to assess incorporation of the matrix and wound healing progress.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources required to apply the matrix are substantially greater than usual. |